MedPath

Safety and Surgical Performance Study of Aurosleek Surgical Blades

Conditions
Cataract
Registration Number
NCT01763593
Lead Sponsor
Aurolab
Brief Summary

To evaluate the safety and surgical effectiveness of surgical blades (Aurosleek) made by Aurolab.

Detailed Description

Cataract till today remains the most common yet treatable cause of blindness accounting for more than 50% of blindness and visual impairment in the developing world. One of the most important features of a blade for cataract surgery is its predictable and repeatable behavior. The surgeon repeatedly and reliably needs to create similar tunnels of the proper length. Aurolab is producing surgical blades (Aurosleek) intended for making incision in cataract surgeries.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
35
Inclusion Criteria
  • Senile cataract
  • Willing to give written informed consent
  • Ability to follow study instructions and likely to complete required visits.
Exclusion Criteria
  • Intraoperative complication including Posterior Capsular Rent and Zonular dialysis
  • Traumatic cataract
  • Uveitis and Complicated cataract
  • One eyed patients

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Physioclinical Characters30 days

Assessment of physio-clinical characteristics of surgical blade such as handling of the blade, sharpness and smoothness of blade.

Handling of the surgical blade will be assessed in grades of difficult to handle,easy to handle and very easy to handle intraoperatively. Sharpness and smoothness of the blade will be rated as poor or optimum while performing cataract surgery.

Secondary Outcome Measures
NameTimeMethod
Post operative complications30 days

The frequency and occurrence of post operative complications such as rhexis tear, posterior capsular rupture, severe corneal edema, severe iritis and anterior vitrectomy.

Post operative complications occurrence due to surgical blade will be observed and graded as none or mild or moderate or severe at surgery and post operative 30 days.

Trial Locations

Locations (1)

Aravind Eye Hospital

🇮🇳

Madurai, Tamilnadu, India

© Copyright 2025. All Rights Reserved by MedPath